Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: J Endocrinol. 2017 Nov;235(2):123–136. doi: 10.1530/JOE-17-0112

Figure 8.

Figure 8

Oncoprint data represents samples from two published sets from the cBioPortal for cancer genomics (Cerami, et al. 2012; Gao, et al. 2013). A. The queried samples represent ELL2 enriched tumors from neuroendocrine prostate cancer (107 samples, whole exome and RNA Seq data of castration resistant adenocarcinoma and castration resistant neuroendocrine prostate cancer (somatic mutations and copy number aberrations)) (Beltran, et al. 2016). B. ELL2 enriched tumors from prostate adenocarcinoma tumor samples with sequencing and CNA data (492 samples, TCGA Research Network: http://cancergenome.nih.gov/). Individual genes are represented as rows, and individual cases or patients are represented as columns. The types of genetic alteration included in both sets are: amplification, deep deletion, mRNA upregulation, mRNA downregulation and missense mutation. cBioPortal data is subjected to scheduled updates.